ICOS is essential for the development of experimental autoimmune myasthenia gravis

SCOTT B., YANG H., Tuzun E., DONG C., FLAVELL R., CHRISTADOSS P.

JOURNAL OF NEUROIMMUNOLOGY, cilt.153, ss.16-25, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 153
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.jneuroim.2004.04.019
  • Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.16-25
  • Anahtar Kelimeler: experimental autoimmune myasthenia gravis, myasthenia gravis, ICOS, B7RP-1, costimulation, autoimmunity, COLLAGEN-INDUCED ARTHRITIS, INDUCIBLE COSTIMULATOR, MOLECULE ICOS, MOTOR ENDPLATE, T-CELLS, LIGAND, CD28, EXPRESSION, INDUCTION, RESPONSES
  • İstanbul Üniversitesi Adresli: Evet

Özet

Lymphocyte costimulation via the inducible costimulatory molecule (ICOS) is required for effective humoral immunity development. Following immunization with Torpedo acetylcholine receptor (AChR), ICOS gene knockout (KO) mice were highly resistant to clinical experimental autoimmune myasthenia gravis (EAMG) development, had less serum AChR-specific immunoglobulins (Igs), and exhibited a diminutive germinal center (GC) reaction in secondary lymphoid tissues. Lymphocyte proliferation and both Th1 and Th2 differentiation in response to AChR and the AChR dominant alpha146-162 peptide were inhibited by the ICOS gene deficiency. ICOS-mediated lymphocyte costimulation is thus vital to the induction of T cell-mediated humoral immunity to AChR and the development of clinical EAMG. (C) 2004 Elsevier B.V. All rights reserved.